Long-term outcomes in germ cell tumor patients treated with POMB/ACE chemotherapy
Author Information
Author(s): R.N. Hitchins, E.S. Newlands, D.B. Smith, R.H.J. Begent, G.J.S. Rustin, K.D. Bagshawe
Primary Institution: Charing Cross Hospital
Hypothesis
Can initial serum tumor marker levels predict long-term survival in patients with metastatic non-seminomatous germ cell tumors?
Conclusion
The study found that using initial serum tumor markers to define poor prognosis is at least as effective as more complicated classification systems.
Supporting Evidence
- The study included 206 consecutive male patients treated for metastatic non-seminomatous germ cell tumors.
- Sensitivity and specificity of the classification systems were found to be moderate, ranging from 71-81% and 52-56%, respectively.
- A simple definition of poor prognosis based on serum tumor markers showed a sensitivity of 80% and specificity of 55%.
Takeaway
Doctors can tell how likely a patient is to survive testicular cancer by looking at certain blood tests, not just by checking how far the cancer has spread.
Methodology
The study analyzed records of 206 male patients treated with POMB/ACE chemotherapy and classified them using various prognostic systems.
Limitations
Some patients had incomplete staging or prior chemotherapy, which may affect the results.
Participant Demographics
Median age was 28 years, with a range from 14 to 61 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website